Table 1.
Patient characteristics
| Characteristic | Patients, n (%) |
|---|---|
| Age at IO Therapy (years) | |
| ≤ 50 | 5 (8%) |
| 51–60 | 14 (21%) |
| 61–70 | 21 (31%) |
| > 70 | 27 (40%) |
| Sex | |
| Female | 31 (46%) |
| Male | 36 (54%) |
| Race | |
| African American | 20 (30%) |
| Caucasian | 47 (70%) |
| Disease Stage | |
| Stage 2a | 2 (3%) |
| Stage 3 | 9 (13%) |
| Stage 4 | 56 (84%) |
| Histology | |
| Adenocarcinoma | 36 (54%) |
| Squamous | 17 (25%) |
| Adenosquamous | 2 (3%) |
| NOS | 12 (18%) |
| Biopsy Site | |
| Primary carcinoma | 30 (45%) |
| Distant metastases | 37 (55%) |
| ECOG performance status | |
| 0 | 23 (34%) |
| 1 | 30 (45%) |
| 2 | 14 (21%) |
| Type of Therapy | |
| ICI Monotherapy | 57 (85%) |
| ICI + Chemotherapy | 10 (15%) |
| ICI therapy received | |
| Nivolumab | 33 (49%) |
| Pembrolizumab | 32 (48%) |
| Nivolumab/ Pembrolizumab | 1 (1%) |
| Atezolizumab | 1 (1%) |
| Line of Therapy | |
| 1st line | 29 (43%) |
| 2nd line + | 38 (57%) |
| Response Status | |
| Response (CR, PR) | 42 (63%) |
| Non-Response (PD, SD) | 25 (37%) |
| IO Score (≥0.09) | |
| Positive, n (%) | 36 (54%) |
| Negative, n (%) | 31 (46%) |
| PD-L1 TPS (≥1%) | |
| Positive, n (%) | 45 (67%) |
| Negative, n (%) | 14 (21%) |
| Missing, n (%) | 8 (12%) |
| TMB (≥10 mut/MB) | |
| Positive, n (%) | 21 (31%) |
| Negative, n (%) | 15 (22%) |
| Missing, n (%) | 31 (46%) |
NOS not otherwise specified, ICI immune checkpoint inhibitor, IO score immuno-oncology score, NSCLC non-small cell lung cancer, PD-L1 TPS PD-L1 immunohistochemistry tumor proportion score, TMB tumor mutational burden
aRecurrent Disease